GlassScriptPhysician profile
Kimberly Brown
NPI 1083084537
$8,412.15
in general payments reported to CMS, 2019-2025
31 companies · $861 in 2025
The $861 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,529 · 2022: $2,374 · 2023: $2,003 · 2024: $1,646 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,510.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,509.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,939.57 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,894.91 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Mylan Specialty L.P. | $614.91 | 2021-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $501.00 | 2021-2025 | Ofev, Jascayd |
| Harmony Biosciences LLC | $469.40 | 2021-2025 | |
| Atricure, INC. | $431.87 | 2021 | |
| Axsome Therapeutics, INC. | $331.60 | 2023-2025 | Sunosi |
| Baxter Healthcare | $249.81 | 2022-2024 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care, Hillrom - Volara System |
| Pfizer INC. | $245.44 | 2023 | |
| Genzyme Corporation | $173.01 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $168.32 | 2021-2025 | Dupixent |
| Gilead Sciences, INC. | $150.48 | 2021-2023 | |
| Inspire Medical Systems, INC. | $140.92 | 2024 | Inspire |
| Mallinckrodt Hospital Products INC. | $139.85 | 2023-2024 | Acthar |
| Abbvie INC. | $139.23 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $115.96 | 2025 | Tecentriq |
| Actelion Pharmaceuticals US, INC. | $99.08 | 2022-2024 | Opsumit, Uptravi |
| Tactile Systems Technology INC | $93.11 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.17 | 2022-2023 | Glassia |
| Inogen, INC. | $65.48 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Electromed, INC. | $60.36 | 2022-2025 | Smartvest |
| Ani Pharmaceuticals, INC. | $54.13 | 2022-2023 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $47.85 | 2021-2024 | |
| Grifols USA, LLC | $41.96 | 2022-2024 | Prolastin-C Liquid |
| Pharmacyclics LLC, An Abbvie Company | $40.01 | 2022-2023 | Epkinly, Imbruvica |
| Verona Pharma, INC. | $36.22 | 2025 | Ohtuvayre |
| Insmed, INC. | $34.60 | 2023-2025 | Arikayce |
| 3b Medical, INC. | $18.85 | 2025 | Luna |
| Paratek Pharmaceuticals, INC. | $17.89 | 2023 | Nuzyra |
| United Therapeutics Corporation | $14.67 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.49 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.